

16 Jun 2024 | News

Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast edition of Five Must-Know Things: Boehringer best in MASH?; biopharma funding on an upswing?; Moderna's combo jab; clinical trial recover from pandemic; and Astellas's US commercial head speaks.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 14 June 2024, including: [Boehringer Ingelheim GmbH](#) best in MASH?; biopharma funding on an upswing?; [Moderna, Inc.](#)'s combo jab; clinical trial recover from pandemic; and [Astellas Pharma, Inc.](#)'s US commercial head speaks.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Boehringer Backs Up Best-In-Class MASH Claims With Fibrosis Data](#)" - Scrip, 7 Jun, 2024.)

(Also see "[Financial Market At The Start Of An Upswing. For Companies With Focused Strategies](#)" - Scrip, 12 Jun, 2024.)

(Also see "[Moderna Pips Pfizer/BioNTech In Combo Jab Race](#)" - Scrip, 10 Jun, 2024.)

(Also see "[What Pandemic? Clinical Trials Shake The COVID-19 Dust Off Their Feet](#)" - Scrip, 12 Jun, 2024.)

(Also see "[Astellas's US Commercial Head Petroutsas On New Launches](#)" - Scrip, 11 Jun, 2024.)

[Click here to explore this interactive content online](#) ✨